Study of an Extended Release (ER) Tablet, Single and Repeated Dosing

A Two-part, Single-centre, Open (Part A) Single Blind (Part B), Randomised, Placebo-controlled Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Doses With and Without Food and Multiple Ascending Oral Doses of AZD1305 Extended-release Tablet in Healthy & Elderly Subj

The purpose is to study the safety and tolerability of increasing doses of AZD1305 and how the medication is metabolised by the body (how it is taken up, distributed, and how it disappears from the body). The study is performed in healthy volunteers.

Inclusion Criteria:

• A body mass index (BMI=weight/height2) of 19 to 27 kg/m2
• Clinically normal physical findings, laboratory values and resting ECG as judged by the investigator

Exclusion Criteria:

• ECG findings outside normal range
• Potassium outside normal reference values